Mobile

An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000848-24

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to determine whether talnetant provides adequate relief of IBS pain and discomfort in any dose group compared to placebo and to determine the safety and tolerability in IBS subjects.

Critère d'inclusion

  • Irritable Bowel Syndrome (IBS)

Liens